AstraZeneca (AZN) European Society of Cardiology Congress 2025 summary

Strategic Vision and Growth Outlook

• Targeting $80 billion in risk-adjusted total revenue by 2030, driven by a diverse portfolio and new launches, with growth not dependent on future M&A.

• Focus on expanding in cardiometabolic diseases, oncology, and rare diseases, leveraging global reach and partnerships.

• Emphasis on innovative therapies targeting overlapping risk factors in cardiorenal and cardiometabolic diseases, including weight management and advanced modalities post-2030.

• Multiple upcoming readouts in oncology, rare disease, and biopharmaceuticals expected over the next 6–12 months.

• Conference featured presentations and Q&A with senior R&D and business leaders, and external clinical experts.

Addressing Unmet Needs in Cardiometabolic Diseases

• Cardiometabolic diseases are leading causes of death, with high prevalence of multi-morbidity in older adults.

• Ambition to transform care by targeting dyslipidaemia, hypertension, heart failure, kidney disease, and weight-related comorbidities.

• Large patient populations remain uncontrolled or at risk despite current therapies, highlighting need for novel mechanisms.

• Pipeline includes innovative combinations and new molecular entities to address multi-organ and multi-risk factor diseases.

• Focus on combination approaches to address overlapping risk factors in cardiorenal and cardiometabolic diseases.

Baxdrostat Clinical Data and Potential

• Baxdrostat, a selective aldosterone synthase inhibitor, showed significant placebo-adjusted reductions in seated systolic BP at 12 weeks (8.7 mmHg for 1 mg, 9.8 mmHg for 2 mg) in hard-to-control hypertension.

• Efficacy was consistent across all pre-specified subgroups, with sustained effects up to 32 weeks and robust 24-hour and nighttime blood pressure control.

• Baxdrostat reduced plasma aldosterone by 60–65% and demonstrated no off-target hormonal effects or significant drug-drug interactions.

• Phase III trial included adults with uncontrolled or resistant hypertension on multiple antihypertensive agents.

• Ambulatory 24-hour and night-time BP also reduced substantially.